Are you Dr. Carey?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5052 W 4th St
Hattiesburg, MS 39402Phone+1 601-261-2587Fax+1 601-264-7426
Summary
- Dr. Thomas Carey, MD is a board certified pathologist in Hattiesburg, Mississippi. He is currently licensed to practice medicine in Mississippi, Montana, and Ohio.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Pathology-Anatomic and Clinical, 1998 - 2000
Baptist Medical CenterResidency, Anatomic and Clinical Pathology, 1995 - 1996
Cleveland Clinic FoundationResidency, Pathology-Anatomic and Clinical, 1990 - 1995
Louisiana State University School of Medicine in New OrleansClass of 1990
Certifications & Licensure
MS State Medical License 2017 - 2025
OH State Medical License 1996 - 2023
MT State Medical License 2000 - 2021
LA State Medical License 1990 - 2001- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 1361 citationsCell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Katherine A Hoadley, Christina Yau, Toshinori Hinoue, Denise M. Wolf, Alexander J. Lazar
Cell. 2018-04-05 - 2759 citationsComprehensive genomic characterization of head and neck squamous cell carcinomasMichael S. Lawrence, Carrie Sougnez, Lee Lichtenstein, Kristian Cibulskis, Eric S. Lander
Nature. 2015-01-29 - 53 citationsCancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma.Steven B. Chinn, Owen A.F. Darr, John H. Owen, Emily Bellile, Jonathan B. McHugh
Head & Neck. 2015-03-01
Press Mentions
This Shot Helps Prevent Cancer. Why Do so Few Men Get It?September 16th, 2021
MDM2-Dependent Sirt1 Degradation Is a Prerequisite for Sirt6-Mediated Cell Death in Head and Neck CancersMarch 16th, 2021
Grant Support
- Biomarkers To Guide Treatment And Improve Survival In Oral/Oropharyngeal CancerNational Institute Of Dental &Craniofacial Research2009–2012
- C3: Tissue And HistopathologyNational Cancer Institute2008–2011
- Defining Antigenic Targets Of Autoimmune Sensorineural Hearing LossNational Institute On Deafness And Other Communication Disorders2006–2011
- Antigenic Targets Autoimmune Sensorineural Hearing LossNational Institute On Deafness And Other Communication Disorders1999–2003
- Predicting Response To Therapy: Detection Of Oral CancerNational Institute Of Dental &Craniofacial Research1999–2003
- Galanin /Galanin Receptors--Markers Of Tumor ProgressionNational Cancer Institute2002
- Chromosome 18 Tumor Suppressor Genes In Oral CancerNational Institute Of Dental &Craniofacial Research1998–2002
- Gene Expression In Auditory Hair CellsNational Center For Research Resources1996–2000
- Antibody Induced Hearing Loss--Model For Immune DeafnessNational Institute On Deafness And Other Communication Disorders1995–1999
- Human Squamous Cell Carcinoma: Culture And SerologyNational Cancer Institute1985–1987
- Monoclonal Antibodies To Human Squamous Cancer AntigensNational Cancer Institute1985–1986
